dc.contributor.author | Moussa, O | |
dc.contributor.author | Bhogal, RH | |
dc.contributor.author | Malietzis, G | |
dc.contributor.author | Fribbens, C | |
dc.contributor.author | Starling, N | |
dc.contributor.author | Gerlinger, M | |
dc.contributor.author | Watkins, D | |
dc.contributor.author | Chau, I | |
dc.contributor.author | Rao, S | |
dc.contributor.author | Cunningham, D | |
dc.contributor.author | Allum, WH | |
dc.contributor.author | Chaudry, A | |
dc.contributor.author | Kumar, S | |
dc.date.accessioned | 2022-04-01T10:47:36Z | |
dc.date.available | 2022-04-01T10:47:36Z | |
dc.date.issued | 2022-01-06 | |
dc.identifier.citation | BJS open, 2022, 6 (1) | |
dc.identifier.issn | 2474-9842 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5059 | |
dc.identifier.eissn | 2474-9842 | |
dc.identifier.eissn | 2474-9842 | |
dc.identifier.doi | 10.1093/bjsopen/zrac003 | |
dc.identifier.doi | 10.1093/bjsopen/zrac003 | |
dc.description.abstract | BACKGROUND: Perioperative FLOT (fluorouracil plus leucovorin, oxaliplatin, and docetaxel) chemotherapy is a recent regimen used to treat resectable oesophagogastric (OG) adenocarcinoma, associated with improved overall survival versus earlier chemotherapy strategies. This study compared short-term perioperative morbidity in a large tertiary centre series of FLOT to a matched cohort receiving ECX/ECF (epirubicin, cisplatin, capecitabine (X) or 5-fluorouracil (F)). METHODS: Consecutive patients completing four perioperative cycles of FLOT and proceeding to surgery with resectable OG adenocarcinoma were included. This was matched to patients from a historic ECX/ECF cohort from the same institution. A propensity score was calculated, and a secondary analysis using a propensity-matched group performed. RESULTS: Cohorts were matched by tumour location and operations performed. In total there were 129 (64.5 per cent) oesophageal and 71 (35.5 per cent) gastric resections (FLOT 57 oesophageal, 43 gastric; ECF/ECX 64 oesophageal, 36 gastric). The median length of stay after surgery was 12 days in the FLOT group versus 15 in ECF/ECX (P = 0.035). There were no significant differences in overall perioperative complications and, specifically, no difference in OG anastomotic leaks, analysed by site (gastric (FLOT 0/79 (0 per cent) versus ECX 2/79 (2.5 per cent); P = 0.123), oesophageal (FLOT 4/121 (3.3 per cent) versus ECX 5/121 (4.1 per cent); P = 0.868) or type of surgery (open FLOT 1/121 (0.8 per cent) versus ECX 3/121 (2.5 per cent); P = 0.368; minimally invasive (FLOT 3/121 (2.5 per cent) versus ECX 2/121 (1.7 per cent); P = 0.555)). There was no statistical difference in leak-related return to theatre, 30-day (FLOT 0 (0 per cent) versus ECX 3/100 (3.0 per cent); P = 0.081), or 90-day (FLOT 0 (0 per cent) versus ECX 2/100 (2.0 per cent); P = 0.155) mortality. CONCLUSION: In terms of surgical complications, FLOT and ECX/ECF were equally safe in patients undergoing resection for OG adenocarcinoma. | |
dc.format | Print | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | OXFORD UNIV PRESS | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Humans | |
dc.subject | Adenocarcinoma | |
dc.subject | Stomach Neoplasms | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Propensity Score | |
dc.subject | Capecitabine | |
dc.title | Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-12-22 | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1093/bjsopen/zrac003 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.relation.isPartOf | BJS open | |
pubs.issue | 1 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials/Gastrointestinal Cancers Clinical Trials (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 6 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Gastrointestinal Cancers Clinical Trials | |
icr.researchteam | Medicine (RMH Smith Cunningham) | |
dc.contributor.icrauthor | Bhogal, Ricky | |
dc.contributor.icrauthor | Gerlinger, Marco | |